Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Completed · Phase 3

Conditions studied: Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition

In brief

RATIONALE: Infrared coagulator ablation may be effective in preventing the development of anal cancer in patients with anal neoplasia PURPOSE: This randomized phase III trial is studying infrared coagulator ablation to see how well it works compared to observation in preventing anal cancer in HIV-positive patients with anal neoplasia.

Key facts

Study ID

NCT01164722

Run by

AIDS Malignancy Consortium

People needed

120

Starts

2011-04-01

Expected to finish

2016-07-01

Last updated by the study team

2020-08-04

Who can join

Age: 27 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA Clinical AIDS Research and Education (CARE) Center — Los Angeles, California, United States
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
• Boston University Cancer Research Center — Boston, Massachusetts, United States
• Laser Surgery Care — New York, New York, United States
• New York Weill Cornell Cancer Center at Cornell University — New York, New York, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Benaroya Research Institute at Virginia Mason Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.